Key result
Multidrug metabolic therapy with dual PPAR agonism improves lipid and glycemic parameters in severe dyslipidemia.
Why the study?
Congenital generalized lipodystrophy presents with severe insulin resistance and metabolic complications, but detailed clinical management reports are limited.
Case Report (n=1)
A multidrug regimen including saroglitazar, icosapent ethyl, pioglitazone-metformin, and basal insulin successfully improved massive hypertriglyceridemia and severe insulin resistance in a patient with congenital generalized lipodystrophy.
May support multidrug regimens in congenital lipodystrophy; leaves open need for controlled trials before broader adoption.
We report a 20-year-old female who presented with acute abdominal pain and vomiting, with a background of diabetes mellitus and severe hypertriglyceridemia since the age of 16 years. Clinical examination revealed a marked paucity of subcutaneous adipose tissue throughout the body. Laboratory investigations confirmed severe insulin resistance with HbA1c (glycated hemoglobin) of 8.5%, massive hypertriglyceridemia (1257 mg/dL), and preserved C-peptide levels (3.75 ng/mL). The clinical phenotype and biochemical profile suggested a diagnosis of congenital lipodystrophy, though genetic confirmation was not feasible due to financial constraints. Congenital lipodystrophy is characterized by ectopic fat accumulation in the liver, muscles, and pancreas, with resultant severe insulin resistance and metabolic complications. Management with dual PPAR agonist therapy (saroglitazar), omega-3 fatty acids (icosapent ethyl), thiazolidinediones (pioglitazone-metformin combination), and basal insulin resulted in significant improvement in lipid and glycemic parameters on subsequent follow-ups.
No takes yet. Share an insight, caveat, or question.
Malik et al. (2026) conducted a case report in Congenital Generalized Lipodystrophy (n=1). Dual PPAR agonist therapy, omega-3 fatty acids, thiazolidinediones, and basal insulin was evaluated. Management with dual PPAR agonist therapy, omega-3 fatty acids, thiazolidinediones, and basal insulin led to significant improvement in lipid and glycemic parameters.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: